Compare · DXCM vs HSAQ
DXCM vs HSAQ
Side-by-side comparison of DexCom Inc. (DXCM) and Health Sciences Acquisitions Corporation 2 (HSAQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HSAQ operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 164.1x HSAQ ($201.6M).
- DXCM has hit the wire 6 times in the past 4 weeks while HSAQ has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for HSAQ).
- Company
- DexCom Inc.
- Health Sciences Acquisitions Corporation 2
- Price
- -
- -
- Market cap
- $33.10B
- $201.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Health Sciences Acquisitions Corporation 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest HSAQ
- SEC Form 5 filed by Medtronic Plc
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-1 filed by Health Sciences Acquisitions Corporation 2
- New insider Papandreou George claimed ownership of 20,000 shares (SEC Form 3)